Clinical Trial Update: Pharmacokinetic/Pharmacodynamic Parameters of NNG-DEPO (Stimus) With Aranesp® (Amgen) in Treatment of Anemia in CKD Patients on Dialysis [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic/pharmacodynamic study evaluating NNG-DEPO (Stimus) in combination with Aranesp for treating anemia in chronic kidney disease patients on…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia of Chronic Kidney Disease
• Chronic Kidney Disease

Drugs mentioned

• ARANESP (DARBEPOETIN ALFA)
• NNG-DEPO (Stimus)

Snippet

Sponsor: Nanogen Pharmaceutical Biotechnology Joint Stock Company | Conditions: Chronic Kidney Disease | Phase 1 | Status: COMPLETED